JPS58138458A - Preparation of capsul dissolved in intestine - Google Patents

Preparation of capsul dissolved in intestine

Info

Publication number
JPS58138458A
JPS58138458A JP2026682A JP2026682A JPS58138458A JP S58138458 A JPS58138458 A JP S58138458A JP 2026682 A JP2026682 A JP 2026682A JP 2026682 A JP2026682 A JP 2026682A JP S58138458 A JPS58138458 A JP S58138458A
Authority
JP
Japan
Prior art keywords
aqueous solution
gelatin
acid
alkali metal
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2026682A
Other languages
Japanese (ja)
Other versions
JPH0347246B2 (en
Inventor
徹 千葉
泰明 武藤
丸山 和政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Etsu Chemical Co Ltd
Original Assignee
Shin Etsu Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Etsu Chemical Co Ltd filed Critical Shin Etsu Chemical Co Ltd
Priority to JP2026682A priority Critical patent/JPS58138458A/en
Publication of JPS58138458A publication Critical patent/JPS58138458A/en
Publication of JPH0347246B2 publication Critical patent/JPH0347246B2/ja
Granted legal-status Critical Current

Links

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 本発明は腸溶性基剤特にはヒドロキレプロピルメチルセ
ルロースアセテートサクシネートの水溶液から腸溶性カ
プセルを製造する方法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a process for preparing enteric capsules from an aqueous solution of an enteric base, particularly hydroxylepropyl methyl cellulose acetate succinate.

腸溶性カプセルは医薬品を封入し服用されるが、従来、
このようなカプセルの製造方法としてはゼラチン製のカ
プセルを腸溶性高分子物質で被覆する方法、腸溶性高分
子物質の有機溶媒溶液に成型ビンを浸漬し成形する方法
、およびゼラチンとセルロースアセテートフタレートあ
るいはヒドロキレプロピルメチルセルロースフタレート
のアルカリ金属塩の水溶液に成型ビンを浸漬し成形する
方法等が知られている。
Enteric-coated capsules are used to enclose pharmaceutical products, but traditionally,
Methods for manufacturing such capsules include coating capsules made of gelatin with an enteric polymeric substance, immersing a molded bottle in an organic solvent solution of an enteric polymeric substance and molding the capsule, and coating gelatin with cellulose acetate phthalate or gelatin. A method is known in which a molding bottle is immersed in an aqueous solution of an alkali metal salt of hydroxypropyl methylcellulose phthalate.

しかしながら、ゼラチン製のカプセルを腸溶性高分子物
質で被覆する方法には、ゼラチンの表面と被覆膜との接
着不良が生じ易く、有機溶媒溶液を使用する方法では溶
媒の回収工程、作業環境汚染、火災燦発対策が必要で、
しかも成品への溶媒ノ残留が懸念される。また前記ゼラ
チンとセルロースアセテートフタレートあるいはヒドロ
キシプロピルメチル々ルロースフタレートのアルカリ金
属塩の水溶液を使用する場合には加水分解を起こしたり
、カプセルがもろい勢の間聰点がある。
However, the method of coating gelatin capsules with an enteric polymer substance tends to cause poor adhesion between the surface of the gelatin and the coating film, and the method of using an organic solvent solution does not contaminate the work environment during the solvent recovery process. , fire prevention measures are required.
Furthermore, there is a concern that solvent may remain in the product. Furthermore, when an aqueous solution of gelatin and an alkali metal salt of cellulose acetate phthalate or hydroxypropyl methyl tululose phthalate is used, hydrolysis may occur or the capsule may become brittle.

本発明者らは前記欠点を解消し、化学的に安定で耐衛曝
性にすぐれたカプセルな製造する方法を種々検討した結
果、ヒドロキシプロピルメチルセルロースアセテートサ
クシネートのアルカリ金属塩とゼラチンを含む水溶液に
成型ビンを浸漬し成型した後、酸水溶液に浸漬処理する
ことにより、きわめてすぐれた腸溶性カプセルを得るこ
とができることを見出し、本発明を完成した。
The present inventors investigated various methods of manufacturing capsules that are chemically stable and have excellent exposure resistance by eliminating the above-mentioned drawbacks, and as a result, they developed an aqueous solution containing an alkali metal salt of hydroxypropyl methylcellulose acetate succinate and gelatin. The present invention was completed based on the discovery that extremely excellent enteric-coated capsules can be obtained by immersing a molded bottle, molding it, and then immersing it in an acid aqueous solution.

以下本発明の詳細な説明する。The present invention will be explained in detail below.

本発明に用いられるヒドロキシプロピルメチルセルロー
スアセテートサクシネート()(PMC−A8)は、他
の腸溶性基剤とは興なってそれ自体カ非常に柔軟性に富
んだ基剤であるため、ゼラチンと併用する場合に、腸溶
性基剤に対するゼラチンの添加の割合を下げてももろく
ならず、強度のすぐれたカプセルを製造することができ
、またゼラチンの添加の割合が下がることにより、胃液
および水に対する安定性が向上するため腸に到達するま
でに破壊される懸念がなく、すぐれた腸溶性の機能を発
揮することができる。また、他の基剤では柔軟性を付与
するためには多量の可塑剤の添加を必要とするが1本発
明の方法では可塑剤の添加は全く必要としないかないし
は少量の添加でよいため、゛可塑剤かにじみ出す等の障
害を起こすことがない。
Hydroxypropyl methylcellulose acetate succinate (PMC-A8) used in the present invention is a very flexible base in itself, unlike other enteric coated bases, so it can be used in combination with gelatin. When the ratio of gelatin added to the enteric base is lowered, it is possible to produce capsules that do not become brittle and have excellent strength, and by lowering the ratio of gelatin added, they are stable against gastric juices and water. Because of its improved properties, there is no fear that it will be destroyed before it reaches the intestines, and it can exhibit excellent enteric-coated functions. In addition, while other bases require the addition of a large amount of plasticizer to impart flexibility, the method of the present invention does not require the addition of plasticizer at all or only requires the addition of a small amount. , ``There is no problem such as plasticizer oozing out.

本発明の方法に使用されるl(PMO−A8はすでに知
られたものであり、例えば酢酸またはプロピオ′ンー等
のカルボン酸を反応媒体として使用し、酢酸ナトリウム
、酢酸カリウム等のカルボン酸のアルカリ金属塩触媒の
存在下に、ヒドロキシプ、ロピルメチルセルロースと無
水酢酸および無水コへり酸とをエステル化反応させる方
法、ある゛いはこのエステル化反応をア七トン等の適当
な溶媒中でピリジン等の塩基性融媒の存在下で行わせる
方法等により製造することができる。本発明の目的にお
いてはこのHPMC−Asとしてグルコース単位1個あ
たりの置換基の平均置換数がヒドロキシプロポキシル基
0,1〜0.8 Jメトキシル基1.4〜l、9、アセ
チル基0.2〜0.8、酸性サクシノイル基0.1〜0
,7であるものが好適とされる。
The l(PMO-A8) used in the process of the present invention is already known, for example by using a carboxylic acid such as acetic acid or propionate as the reaction medium, and by using an alkali of the carboxylic acid such as sodium acetate or potassium acetate. A method of esterifying hydroxypropyl methyl cellulose with acetic anhydride and chelic anhydride in the presence of a metal salt catalyst, or carrying out this esterification reaction in a suitable solvent such as acetate with pyridine. For the purpose of the present invention, HPMC-As has an average number of substituents per glucose unit of 0 hydroxypropoxyl groups. ,1-0.8 J methoxyl group 1.4-l, 9, acetyl group 0.2-0.8, acidic succinoyl group 0.1-0
, 7 is preferred.

ゼラチンはその水溶液(浸漬液)に成型ビンを浸漬し引
上げたときに、浸漬液が流れてカプセルの肉厚が不均一
なものとなるのな防止するためのものであり、その効果
を発揮させるためには浸漬液から成型ビンを引上げた後
速かに20℃以下に冷却することが望ましく、またゼラ
チンの添加量は、もし少なすぎるとその効果がなく、ま
た多すぎると腸溶性の機能が阻害されるほか乾燥後カプ
セルがもろくなるので、HPMC−Asの1重量部に対
して0,05〜0.51量部の範囲とすることが望まし
い。
Gelatin is used to prevent the capsule from becoming uneven in thickness due to the dipping liquid flowing when a molded bottle is immersed in the aqueous solution (immersion liquid) and pulled out. In order to achieve this, it is desirable to quickly cool the molded bottle to below 20°C after pulling it out of the immersion liquid. Also, if the amount of gelatin added is too small, it will not be effective, and if it is too large, the enteric function will be impaired. In addition to being inhibited, the capsule becomes brittle after drying, so it is desirable that the amount ranges from 0.05 to 0.51 parts by weight per 1 part by weight of HPMC-As.

水溶液(浸漬液)を調製する方法は特に規制されるもの
で呟ないが、)(PMO−人8の溶解を速やかに行うた
めには、まずI(PMO−A8を水に分散゛したのちか
くはんしながら塩基の水溶液を添加するとよい。この目
的に用いられる塩基としては水酸化ナトリウム、水酸化
カリウム、炭酸水素ナトリウム、炭酸水素カリウム、炭
酸ナトリウム、炭酸カリウムなどが例示される。これら
塩基の使がこの60%よりも少ないと)(PMC−As
の水への溶解が十分に行われないおそれが生じ、カプセ
ルの表面があれることが懸念される。また溶解をより速
やかに行う目的で該当量で100%を越える←番→過剰
を用いてもさしつかえないが、この場合C二はHPMC
−As中のエステル結合が加水分解されるのを防ぐため
に、これを酸で中和することにより過剰のアルカリによ
る弊害をなくすゼラチンの溶解は、上記のHPMC−A
8の溶液にゼラチンを加えてかくはんしながら加熱溶解
する、あるいはHPMC−A8の溶液に別に溶解したゼ
ラチン水溶液を加熱かくはんしながら混合すればよく、
これによりビン成型用浸漬液としてのHPMC−人8と
ゼラ′チンを主体とする水溶液が得られる。
The method of preparing an aqueous solution (immersion solution) is not particularly regulated, but in order to quickly dissolve PMO-A8, first disperse PMO-A8 in water and then stir. It is recommended to add an aqueous solution of a base while adding the base. Examples of bases used for this purpose include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, and potassium carbonate. If it is less than 60%) (PMC-As
There is a possibility that the dissolution in water may not be sufficient, and there is a concern that the surface of the capsule may become rough. In addition, for the purpose of dissolving more quickly, it is possible to use an excess amount exceeding 100%, but in this case, C2 is HPMC.
- In order to prevent the ester bonds in As from being hydrolyzed, gelatin is dissolved by neutralizing them with acid to eliminate the harmful effects of excess alkali.
Add gelatin to the solution in step 8 and heat and dissolve while stirring, or mix gelatin aqueous solution separately dissolved in HPMC-A8 solution while heating and stirring.
As a result, an aqueous solution containing HPMC-8 and gelatin as a dipping liquid for bottle molding is obtained.

カプセルの成型は、流動パラフィン、カルナウバワック
スなどの離型剤を塗布した成型ビンを上記のようにして
作った浸漬液に浸漬し、引上げ、冷却したのちあるいは
さらに予備乾燥したのち、これを酸水溶液中に浸漬して
酸処理を施こし、ついで乾燥したのちビンから成型体を
はずし切断等の必要な後工程を施こすことにより行われ
る。
To mold capsules, a molding bottle coated with a mold release agent such as liquid paraffin or carnauba wax is immersed in the immersion liquid made as described above, pulled up, cooled, or pre-dried, and then soaked in acid. This is done by immersing the molded body in an aqueous solution, subjecting it to acid treatment, then drying it, removing the molded body from the bottle, and performing necessary post-processes such as cutting.

なお、浸漬後の冷却温度は浸漬液が流れてカプセルの肉
厚が不均一となるのを防止するために20℃以下望まし
くは18℃以下とすることが望ましい。また上記酸処理
は必須の工程であってこの処理を施こさないと−HPM
C−Asのアルカリ金属塩は水溶性であるため、服用し
てから胃に到達するまでにカプセルが破壊され、腸溶性
の機能が失われる懸念があるが、酸処理を施こすことに
よりHPMCj−A8のアルカリ金属塩が水(:不溶の
遊離の状態にもどるために、耐水性が得られ、十分にそ
の機能を発揮することができる。この目的のために使用
される酸としては、塩酸、硫酸、硝酸、りん酸などのモ
ノカルボン酸類、シュウ酸、マロン酸、コハク酸、アジ
ピン酸、マレイン酸、フマル酸、リンゴ酸、酒石酸など
の多価カルボン酸が例示される。
Note that the cooling temperature after immersion is desirably 20° C. or lower, preferably 18° C. or lower in order to prevent the immersion liquid from flowing and making the wall thickness of the capsule uneven. In addition, the above acid treatment is an essential step, and if it is not performed -HPM
Since the alkali metal salt of C-As is water-soluble, there is a concern that the capsule will be destroyed and the enteric function will be lost between the time it is taken and the time it reaches the stomach, but by acid treatment, HPMCj- Since the alkali metal salt of A8 returns to a water-insoluble free state, water resistance can be obtained and its function can be fully exerted.As acids used for this purpose, hydrochloric acid, Examples include monocarboxylic acids such as sulfuric acid, nitric acid, and phosphoric acid, and polyhydric carboxylic acids such as oxalic acid, malonic acid, succinic acid, adipic acid, maleic acid, fumaric acid, malic acid, and tartaric acid.

上記酸は水溶液として用いられ、その濃度は酸の種類に
よって異なるが通常3〜30%〕範囲カ用い範囲カケな
お、鉱酸類を用いた場合には処通条件によってはカプセ
ルに鉱酸類が残存し、HPMe−人Sの分解・変質を起
こすことがあるので、このような場合には酸処理の後で
洗浄することが望ましい。
The above acid is used as an aqueous solution, and its concentration varies depending on the type of acid, but is usually 3 to 30%] Note that when mineral acids are used, mineral acids may remain in the capsule depending on the processing conditions. , HPMe-S may decompose or change in quality, so in such cases it is desirable to wash after acid treatment.

カプセルの肉厚は浸漬液中におけるHPMO−A8およ
びゼラチンの濃度、および温度によって決定されるが、
一般には濃度15〜401量%、浸漬温度25〜40℃
とすることが望ましい。肉薄のカプセルを得ることが目
的の場合には低濃度の浸漬液を、また肉厚のカプセルを
得ることが目的の場合には高濃度の浸漬液をそれぞれ使
用することが望ましい。
The wall thickness of the capsule is determined by the concentration of HPMO-A8 and gelatin in the immersion liquid, and the temperature.
Generally, the concentration is 15-401% by weight, and the soaking temperature is 25-40℃.
It is desirable to do so. When the purpose is to obtain thin-walled capsules, it is desirable to use a low-concentration immersion liquid, and when the purpose is to obtain thick-walled capsules, it is desirable to use a high-concentration immersion liquid.

なお、浸漬液には必要に応じて着色剤、きよう味剤、可
塑剤、充てん剤などの各種添加剤を配合することはさし
つかえない。
Note that various additives such as colorants, flavoring agents, plasticizers, and fillers may be added to the immersion liquid as necessary.

つぎに具体的実施例をあげる。Next, a specific example will be given.

実施例 1 グルコース単位1個あたりの平均置換数が、ヒドロキシ
プロポキシル基0.24、メトキシル基l、87、アセ
チル基0.44、サクシノイル基0.24であるHPM
C−Asの20(lを氷9201Pにかくはんしながら
加え、よく分散させてから、10%水酸化ナトリウム水
溶液781P1徐々に添加してHPMO−八Sの水溶液
を得た。これにゼラチン25ノを添加した後50℃に昇
温し、3時間かくはんして浸漬液を調整した。この浸漬
液を30℃に保ち、離型剤としてカルナウバワックスを
塗布したステンレス製成型ビンを浸漬して引きあげ乾燥
した後、ビンから成型体をはずし、必要な後工程を施こ
しカプセルを得た。
Example 1 HPM in which the average number of substitutions per glucose unit is 0.24 hydroxypropoxyl groups, 87 methoxyl groups, 0.44 acetyl groups, and 0.24 succinoyl groups
Add 20 liters of C-As to ice 9201P while stirring, disperse well, and then gradually add 10% sodium hydroxide aqueous solution 781P to obtain an aqueous solution of HPMO-8S. To this, add 25 liters of gelatin. After the addition, the temperature was raised to 50°C and stirred for 3 hours to prepare an immersion liquid.The immersion liquid was kept at 30°C, and a stainless steel molding bottle coated with carnauba wax as a mold release agent was immersed and pulled out. After drying, the molded body was removed from the bottle and subjected to necessary post-processing to obtain capsules.

また別途、成型ビンを浸漬引きあげ、室温で約1時間風
乾した後15℃の10%塩酸水溶液に5分間浸漬した後
、20秒間水に浸漬し水洗したものおよび10%クエン
酸水溶液に5分間浸漬したものを乾燥し上記と同様の操
作によりカプセルを得た。
Separately, molded bottles were immersed, pulled out, air-dried for about 1 hour at room temperature, immersed in 10% hydrochloric acid aqueous solution at 15°C for 5 minutes, immersed in water for 20 seconds, rinsed with water, and immersed in 10% citric acid aqueous solution for 5 minutes. The dried product was dried and capsules were obtained in the same manner as above.

こうして得たカプセルに乳糖粉末を充てんし、ボディと
キャップのかん合部を上記HPMC−A8の20%アセ
トン溶液でシールしたものについて、日本薬局方@lO
改正に基づ<Ill液(T)Hl、2)、第2液(pH
6,8)および水道水中での変化の様子を観察したとこ
ろ、次の表に示すとおりの結果が得られた。
The capsules thus obtained were filled with lactose powder, and the joint between the body and the cap was sealed with a 20% acetone solution of HPMC-A8.
Based on the amendment < Ill liquid (T) Hl, 2), 2nd liquid (pH
6, 8) and their changes in tap water, the results shown in the following table were obtained.

この200?を水840?にかくはんしながら加え、よ
く分散させてから10%水酸化カリウム77ノを徐々に
加えてHPM(3−A8の水溶液な得た。
This 200? Water 840? The mixture was added to the mixture while stirring, and after being well dispersed, 77 g of 10% potassium hydroxide was gradually added to obtain an aqueous solution of HPM (3-A8).

この液を40℃に保ち、これに別途調整した40℃の3
0%ゼラチン水溶液100?な添加し、3時間かくはん
を続は浸漬液とした。この浸漬液を40℃のまま保ち、
離型剤として流動パラフィンを塗布したステンレス製成
型ビンを浸漬し、実施例1と同様にカプセルな得た。
This solution was kept at 40°C, and a separately adjusted 3°C temperature
0% gelatin aqueous solution 100? The mixture was then stirred for 3 hours to prepare the immersion liquid. Keep this immersion liquid at 40℃,
A stainless steel molding bottle coated with liquid paraffin as a mold release agent was immersed to obtain capsules in the same manner as in Example 1.

また別途、実施例1と同様に塩酸処理したカプセルおよ
びlO%マレイン鹸水溶液で3分間処理したカプセルを
得、実施例1の方法にしたがいカプセルの試験を行った
ところ、次の表に示すとおりの結果が得られた。
Separately, capsules treated with hydrochloric acid and capsules treated with 10% maleic soap aqueous solution for 3 minutes in the same manner as in Example 1 were obtained, and the capsules were tested according to the method of Example 1. The results were obtained.

□■ 手続補正書 昭和s7弓■ 3月 2311 1.11訂庁長官 島田妻構  殿 1.1G件の表小 昭和s1年持重顧第2G!6II号 2、発明の名称 腸溶性カプセルの製造方法 3、?山王をする名″ ・19件との関係特許出願人 名称 (11011)信越化学工業株式会社4、代 理
 人 住 所 〒103東京都中央区日本橋本町4丁目9番地
永ガビル〔%:話東京(27G) 0858.085 
G)6、補正の月象 明細書 (補正事項) 明細書第9ページ6行の[りん酸などのモノカルボン#
*、Jを 「りん酸などの無機酸類、酢酸、プロピオン酸、安息香
酸などのモノカルボンi[1lll、 Jと補正する。
□■ Procedural amendment document Showa s7 bow ■ March 2311 1.11 Correction Agency Director Shimada Tsuma-Ko 1.1 G table Small Showa s1 year maintenance review 2nd G! 6II No. 2, Name of the invention Method for manufacturing enteric-coated capsules 3, ? Name of Sanno ・Name of patent applicant related to 19 cases (11011) Shin-Etsu Chemical Co., Ltd. 4, Agent Address 4-9 Nihonbashi Honmachi, Chuo-ku, Tokyo 103 Naga Gabil [%: Story Tokyo ( 27G) 0858.085
G) 6. Amended lunar specification (amendment matters) [Monocarboxylic acid such as phosphoric acid #] on page 9, line 6 of the specification
*, J is corrected as ``Inorganic acids such as phosphoric acid, monocarboxylic acid such as acetic acid, propionic acid, benzoic acid, etc.

以上that's all

Claims (1)

【特許請求の範囲】 1、 ヒドロキシプロピルメチルセルロースアセチ−ト
チクシネートのアルカリ金属塩とゼラチンを含む水溶液
に成型ビンを浸漬し成型した後。 酸水溶液に浸漬処理することを特徴とする腸溶性カプセ
ルの製造方法 2、 ヒドロキシプロピルメチルセルロースアセテート
サクシネートを水に分散させ、かくはん下に塩基および
ゼラチンを加え溶解させて得た水溶液を用いる特許請求
の範囲第1項記載の腸溶性カプセルの製造方法 3、 ヒドロキレプロピルメチルセルロースアセテート
サクシネートのアルカリ金属塩1重量部に対するゼラチ
ンの割合が0.05〜0.5重量部であることを特徴と
する特許請求の範囲181項記載の腸溶性カプセルの製
造方法 4、  前記ヒドロキシプロピルメチルセルロースアセ
チ−トチクシネートのアルカリ金属塩において、アルカ
リ金属がヒドロキレプロピルメチルセルロースアセチ−
トナクシネートの酸性サクシノイル基に対して60%以
上の当量であることを特徴とする特許請求の範囲ll!
1項記載の腸溶性カプセルの製造方法
[Claims] 1. After immersing a molding bottle in an aqueous solution containing gelatin and an alkali metal salt of hydroxypropyl methyl cellulose acetate thixinate and molding. Method 2 for producing enteric-coated capsules, characterized by immersion treatment in an acid aqueous solution, which uses an aqueous solution obtained by dispersing hydroxypropyl methyl cellulose acetate succinate in water, adding and dissolving a base and gelatin while stirring. Method 3 for producing enteric-coated capsules according to scope 1, a patent characterized in that the ratio of gelatin to 1 part by weight of the alkali metal salt of hydroxypropyl methyl cellulose acetate succinate is 0.05 to 0.5 part by weight. 4. A method for producing enteric-coated capsules according to claim 181, wherein in the alkali metal salt of hydroxypropylmethylcellulose acetate, the alkali metal is hydroxypropylmethylcellulose acetate.
Claim 11, characterized in that the equivalent is 60% or more with respect to the acidic succinoyl group of tonaccinate!
Method for producing enteric-coated capsules according to item 1
JP2026682A 1982-02-10 1982-02-10 Preparation of capsul dissolved in intestine Granted JPS58138458A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026682A JPS58138458A (en) 1982-02-10 1982-02-10 Preparation of capsul dissolved in intestine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2026682A JPS58138458A (en) 1982-02-10 1982-02-10 Preparation of capsul dissolved in intestine

Publications (2)

Publication Number Publication Date
JPS58138458A true JPS58138458A (en) 1983-08-17
JPH0347246B2 JPH0347246B2 (en) 1991-07-18

Family

ID=12022385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2026682A Granted JPS58138458A (en) 1982-02-10 1982-02-10 Preparation of capsul dissolved in intestine

Country Status (1)

Country Link
JP (1) JPS58138458A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59193816A (en) * 1983-04-19 1984-11-02 Morishita Jintan Kk Preparation of enteric soft capsule
JPH039755A (en) * 1989-06-08 1991-01-17 Shin Etsu Chem Co Ltd Preparation of medical hard capsule
US5071706A (en) * 1989-08-31 1991-12-10 Eurand America, Incorporated Oily, free-flowing, microcapsules
WO2000025760A1 (en) * 1998-10-29 2000-05-11 Shionogi Qualicaps Co., Ltd. Process for producing hard capsule
JP2004513182A (en) * 2000-06-07 2004-04-30 ツアン、ハオ Oral formulation for specific colon delivery and method for producing the same
JP2006508021A (en) * 2002-03-26 2006-03-09 ユーロ−セルティーク エス.エイ. Sustained release gel coating composition
JP2015518005A (en) * 2012-05-02 2015-06-25 キャプシュゲル・ベルジウム・エヌ・ヴィ Hydroxypropyl methylcellulose acetate succinate (HPMCAS) aqueous dispersion
JP2018008886A (en) * 2016-07-12 2018-01-18 信越化学工業株式会社 Composition for enteric hard capsule and method for producing enteric hard capsule
US9925148B2 (en) 2010-10-26 2018-03-27 Capsugel Belgium Nv Bulk enteric capsule shells
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US10813886B2 (en) 2013-11-04 2020-10-27 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4942819A (en) * 1972-07-20 1974-04-22
JPS55146160A (en) * 1979-04-28 1980-11-14 Shinetsu Chemical Co Enteric coating capsule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4942819A (en) * 1972-07-20 1974-04-22
JPS55146160A (en) * 1979-04-28 1980-11-14 Shinetsu Chemical Co Enteric coating capsule

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59193816A (en) * 1983-04-19 1984-11-02 Morishita Jintan Kk Preparation of enteric soft capsule
JPH039755A (en) * 1989-06-08 1991-01-17 Shin Etsu Chem Co Ltd Preparation of medical hard capsule
JPH0634807B2 (en) * 1989-06-08 1994-05-11 信越化学工業株式会社 Method for manufacturing hard capsules for medicine
US5071706A (en) * 1989-08-31 1991-12-10 Eurand America, Incorporated Oily, free-flowing, microcapsules
WO2000025760A1 (en) * 1998-10-29 2000-05-11 Shionogi Qualicaps Co., Ltd. Process for producing hard capsule
US6413463B1 (en) 1998-10-29 2002-07-02 Shionogi Qualicaps Co., Ltd. Process for producing hard capsule
JP2004513182A (en) * 2000-06-07 2004-04-30 ツアン、ハオ Oral formulation for specific colon delivery and method for producing the same
JP2011201912A (en) * 2002-03-26 2011-10-13 Euro-Celtique Sa Sustained-release gel coated composition
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
JP4790219B2 (en) * 2002-03-26 2011-10-12 ユーロ−セルティーク エス.エイ. Sustained release gel coating composition
JP2006508021A (en) * 2002-03-26 2006-03-09 ユーロ−セルティーク エス.エイ. Sustained release gel coating composition
US9925148B2 (en) 2010-10-26 2018-03-27 Capsugel Belgium Nv Bulk enteric capsule shells
JP2015518005A (en) * 2012-05-02 2015-06-25 キャプシュゲル・ベルジウム・エヌ・ヴィ Hydroxypropyl methylcellulose acetate succinate (HPMCAS) aqueous dispersion
US10463625B2 (en) 2012-05-02 2019-11-05 Capsugel Belgium Nv Bulk enteric capsule shells
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
US10898440B2 (en) 2012-05-02 2021-01-26 Capsugel Belgium Nv Bulk enteric capsule shells
US10813886B2 (en) 2013-11-04 2020-10-27 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
JP2018008886A (en) * 2016-07-12 2018-01-18 信越化学工業株式会社 Composition for enteric hard capsule and method for producing enteric hard capsule
US11141381B2 (en) 2016-07-12 2021-10-12 Shin-Etsu Chemical Co., Ltd. Composition for enteric hard capsule and method for producing enteric hard capsule

Also Published As

Publication number Publication date
JPH0347246B2 (en) 1991-07-18

Similar Documents

Publication Publication Date Title
JPS58138458A (en) Preparation of capsul dissolved in intestine
JP4780898B2 (en) Pectin film composition
TWI472323B (en) Aqueous composition for enteric hard capsule, method of preparing enteric hard capsule,and enteric hard capsule prepared using the method
US4547571A (en) Process for preparing carboxymethyl ethyl cellulose suitable for enteric coating
JPS6281402A (en) Production of acidic dicarboxylic acid ester of cellulose ether
WO1997017065A1 (en) Cellulose acetate phthalate enteric coating compositions
JP2003510348A (en) IMPROVED PHARMACEUTICAL COMPOSITION AND PROCESS FOR PRODUCING THE SAME
JPH06116139A (en) Hard capsule
TWI587880B (en) Can be made into the composition of enteric capsule shell, enteric capsule shell and its process
JP6795587B2 (en) Aqueous composition containing dispersed esterified cellulose ether
JPS62266060A (en) Production of medical hard capsule
US3022287A (en) Method of preparing cellulose esters of trimellitic acid
JPH08245423A (en) Aqueous enteric coating solution
JP2866746B2 (en) Gelatin film
JPS59193816A (en) Preparation of enteric soft capsule
JPS6051124A (en) Enteric coating liquid
JP3868376B2 (en) Method for producing cellulose derivative aqueous dispersion
JP3017412B2 (en) Method for producing base for coating solid enteric preparation
JPH0128043B2 (en)
JPH08269101A (en) Dissolution of carboxymethylcellulose sodium salt
JPS6355525B2 (en)
JP7397886B2 (en) Hard capsules with improved mechanical strength and oxygen permeability based on cellulose derivatives
CN113388162B (en) Film-forming composition and film
JP2925284B2 (en) Packaging material
JPS607492B2 (en) enteric-coated capsules